CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 123 enrolled
Drug / intervention
Sargramostim +1 moredrug
Likely dose
Sargramostim 125 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04411680
NCT04411680Phase 2Completed
CompareCT.gov

A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia

Partner Therapeutics, Inc.·interventional·Posted Jun 2, 2020·Updated Aug 23, 2023

In Brief

A Phase 2 clinical trial evaluating Sargramostim and Standard of care for COVID-19 and SARS-CoV-2. Completed, enrolled 123 participants across 11 sites.

Detailed Summary

The purpose of this research is to find out if a drug (sargramostim) also known as Leukine® could help patient recover faster from COVID-19. Sargramostim may help the lungs recover from the effects of COVID-19, and this research study will help to find this out.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, SARS-CoV-2
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2, 2020
Enrollment StartAug 18, 2020
Primary CompletionMar 2, 2021
Study CompletionMay 19, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.1 years ago

Interventions

Sargramostimdrug

Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). Dosage for inhaled sargramostim: 125 mcg twice a day. Dosage for intravenous sargramostim: 125mcg/m2/day given over a 4 hour period.

Standard of caredrug

Standard of care for COVID-19